EUVIMEDEUVIMED entdecken
Crossref

Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis

Jiawen Huang, Tangli Xiao, Jun Zhang, Yan Li, Liangyu Yin, Chun Zhou, Shaobo Wang, Jiachuan Xiong, Jinghong Zhao iD

Journal of Nephrology · 16.06.2026 · 39 (2) · 335-343

DOI: 10.1093/joneph/aajaf052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nephrology, online erschienen am 27.02.2026. Verfasst von Jiawen Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of K…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Phenylpropionates, Pyridazines, Endothelin A Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key project of Chongqing technology development and application program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proteinuria and hematuria are both significant predictors of impaired kidney function in IgA nephropathy (IgAN). We evaluated the efficacy and safety of ambrisentan, a selective endothelin A receptor antagonist, as adjunctive therapy in a real-world cohort of high-risk IgAN patients.

Methods

In this retrospective, single-center study, we analyzed 169 patients with biopsy-proven IgAN who received adjunctive ambrisentan for ≥6 months. A propensity score-matched historical control group (138 pairs) was generated from patients receiving standard care prior to the ambrisentan era. Laboratory test results were gathered at baseline, and at 3 and 6 months. A generalized estimating equation model was employed to adjust for potential confounders.

Results

In the full ambrisentan cohort (n = 169), median urinary protein-to-creatinine ratio (UPCR) decreased significantly by 58.4% (95% confidence interval [CI], 49.8–62.3) at 6 months, with 75.7% of patients achieving a ≥30% reduction. Hematuria was also significantly reduced (P < .001), and kidney function remained stable. Compared to the matched controls, the ambrisentan group (n = 138 after propensity score-matching) demonstrated a greater median relative reduction in UPCR (−59.7% vs. −53.7%; P = .015). However, a decrease in hemoglobin levels was observed, with an increased incidence of anemia. The proteinuria-lowering effect was enhanced in patients concurrently receiving angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARBs) or finerenone.

Conclusions

In this analysis incorporating a matched historical control, adjunctive ambrisentan significantly reduced proteinuria and hematuria in patients with IgAN without affecting kidney function. The proteinuria-lowering effect was more pronounced when ambrisentan was added to an ACEi/ARB or finerenone. Notably, a significant decline in hemoglobin levels was observed, indicating a need for monitoring. These results warrant further prospective trials to confirm the long-term renal benefits and safety of ambrisentan in IgAN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAPhenylpropionatesPyridazinesEndothelin A Receptor AntagonistsHumansRetrospective StudiesFemaleMaleAdultTreatment OutcomeProteinuriaMiddle AgedHematuriaTime FactorsCreatinineDrug Therapy, CombinationKidneyPropensity ScoreBiomarkers

Stichwörter der Autor:innen

ambrisentanhematuriaimmunoglobulin A nephropathyproteinuria

Substanzen

ambrisentanPhenylpropionatesPyridazinesEndothelin A Receptor AntagonistsCreatinineBiomarkers

Autor:innen und Institutionen

  • Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University,…

ORCID-Profile: Jinghong Zhao

Förderung

  • National Natural Science Foundation of China
  • Key project of Chongqing technology development and application program

Zitieren

APA

Huang, J., Xiao, T., Zhang, J., Li, Y., Yin, L., Zhou, C., Wang, S., Xiong, J., & Zhao, J. (2026). Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis. Journal of Nephrology, 39(2), 335-343. https://doi.org/10.1093/joneph/aajaf052

Vancouver

Huang J, Xiao T, Zhang J, Li Y, Yin L, Zhou C, et al. Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis. Journal of Nephrology. 2026;39(2):335-343. doi:10.1093/joneph/aajaf052

BibTeX
@article{Huang2026,
  author = {Huang, Jiawen and Xiao, Tangli and Zhang, Jun and Li, Yan and Yin, Liangyu and Zhou, Chun and Wang, Shaobo and Xiong, Jiachuan and Zhao, Jinghong},
  title = {Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis},
  journal = {Journal of Nephrology},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {335--343},
  doi = {10.1093/joneph/aajaf052}
}
Kostenlos starten →